Paul Hastings has strengthened its Food and Drug Administration (FDA) practice by appointing Eva A. Temkin as chair, landing in Washington, D.C.
Temkin’s professional background is notably robust, with expertise focused on regulatory, litigation, and transactional matters that involve biomedical products regulated by the FDA. She has held titles such as the Associate Chief Counsel at the FDA’s Office of Chief Counsel and director of policy for the Office of Therapeutic Biologics and Biosimilars. Prior to her steady transition to Paul Hastings, she was a valued member of King & Spalding.
The arrival of Temkin marks a pivotal moment in Paul Hastings’ persistent efforts to further fortify their FDA practice. For legal professionals navigating the invariably complex regulatory terrains of biomedical products, this development enlightens the organization’s commitment to regulatory law prowess. Meanwhile, it also points to an increase of skill diversity in the firm’s existing roster of legal experts –– ultimately ensuring their clients receive the optimal level guidance on related matters.
Read more about the appointment here.